“Turn on, tune in, drop out” was a rallying cry for liberation. “What a long, strange trip it’s been” is how we nostalgically narrate the aftermath. Psychedelic-assisted therapy now sits somewhere between those two cultural bookends: a rapidly professionalizing clinical enterprise and a booming, loosely regulated marketplace of “retreats” selling healing, insight, and transcendence.

The science behind psychedelics is more real than ever. So are the risks. The problem is that public access is expanding faster than safety infrastructure, standards, and honest expectations.

A new qualitative study in JAMA Network Open offers a rare look behind the curtain of publicly advertised psychedelic retreats, and what it found should concern anyone who cares about patient safety, public health, and the credibility of this emerging field.

What the retreat study found: Variability masquerading as “protocol”

Representatives from 49 organizations advertising retreats to English-speaking consumers were interviewed. Most were U.S.-based, and only a small minority described themselves as medical.

Substances offered were wide-ranging, often multiple per retreat. Ayahuasca and psilocybin were the most common. A substantial number offered more than one psychedelic substance, and some combined multiple psychedelics within a single retreat schedule. That matters because combining substances, and stacking sessions, increases physiologic and psychiatric uncertainty in settings where monitoring may be minimal.

Participant screening existed, but it was inconsistent and often self-report dependent. All organizations collected medical histories; about three-quarters excluded participants with certain conditions, most commonly psychosis and bipolar disorder. Yet the study authors highlight a central vulnerability: Screening that relies on self-report can fail, particularly when participants are desperate for relief from depression, PTSD, or addiction and may minimize symptoms to gain entry.

Medication “washout” was nearly universal and highly variable. Most organizations required or recommended stopping prescription medications, with suggested washout periods ranging from one day to more than six weeks. This practice is perilous. Abrupt discontinuation of antidepressants carries known risks (withdrawal, relapse, destabilization) and may create the very psychiatric vulnerability that makes an adverse psychedelic experience more likely.

Medical presence was common but not guaranteed, and credentials were not always transparent. About two-thirds worked with a licensed health professional or someone with emergency-response training, and about two-thirds reported such a person present at least some of the time. That still leaves ample room for catastrophic outcomes when “at least some of the time” becomes the wrong patient, the wrong weekend, or the wrong complication.

Integration support was universal but often informal. Every organization offered some form of integration, yet it varied widely and was frequently optional and loosely structured, such as sharing circles or peer-led discussions. In clinical trials, preparation and integration are not decorative add-ons; they are core safety and risk-mitigation procedures.

Finally, the study grounds these concerns in sobering reality. Between 1994 and 2022, at least 58 deaths were reported during ayahuasca retreats, attributed to causes including homicide, suicide, cardiac events, drowning, and toxic adulterants, events plausibly preventable with rigorous screening and medical safeguards.

The bigger context: Psilocybin is leaving the clinic faster than the clinic can follow

A JAMA Psychiatry review, “Psilocybin Outside the Clinic,” describes a widening gap between tightly controlled clinical trials and real-world use. In trials, risks are mitigated through structured preparation, standardized dosing, trained facilitators, and careful screening. Outside the clinic, psychedelic use more often co-occurs with alcohol or cannabis, and adverse-event signals increasingly appear in poison control and emergency department data.

Two findings deserve emphasis. First, potency in natural products is wildly variable. Testing from decriminalized regions shows more than twentyfold differences in psilocybin content across mushroom samples. Results from trials using standardized, synthetic psilocybin do not automatically generalize to mushrooms grown and dosed in the wild.

Second, public health monitoring is lagging behind demand. The review argues for a shift away from exclusive focus on efficacy trials toward real-world safety research: adverse-event surveillance, product testing, harm-reduction strategies, and age-specific risk assessment.

Rare outcomes also matter when exposure expands. While hallucinogen persisting perception disorder has not been observed in controlled psilocybin trials, persistent negative psychological effects have been documented outside clinical settings, including cases requiring hospitalization and electroconvulsive therapy.

The lesson is not that psychedelics are inherently dangerous. It is that a culture that frames deterioration as “spiritual resistance” and discourages medical help is itself a safety hazard, one that clinicians will inevitably be asked to manage after the fact.

What responsible integration should look like

Across recent consensus statements and harm-reduction viewpoints, several principles converge. Policymakers and regulators should establish enforceable minimum safety standards for any commercialized psychedelic service, including retreats. These standards must go beyond self-reported screening and promotional claims to include verified medical and psychiatric screening, documented emergency response plans, and explicit pathways to local medical care.

Medication discontinuation deserves particular caution. When washout from benzodiazepines, antidepressants, or other psychiatric medications is required or encouraged, it should be treated as a medical decision, coordinated with the prescribing clinician, individualized to the patient, and relapse-aware. Protocol-driven tapering managed by email and deadlines rather than clinical judgment creates avoidable risk.

Regulators should also invest early in surveillance. Adverse-event reporting systems must include nonclinical and commercial settings, where psychedelic use is expanding fastest. Where legal, product testing should be mandatory; wide variability in psychedelic potency is a dose-control problem, not a philosophical one.

Clinicians, meanwhile, should engage directly with patients about psychedelic plans, asking about substances, dosing forms, settings, and co-use of other drugs, and be prepared to manage post-psychedelic anxiety, insomnia, mood destabilization, or trauma symptoms. For the public, basic guardrails apply: Avoid retreats that discourage medical care, cannot explain emergency procedures, mandate unsupervised medication washout, or stack multiple psychedelics in a single program.

Psychedelics may yet become an important tool in mental health care. But legitimacy will not be earned through anecdotes, branding, or borrowed mystique. It will be earned by building systems capable of handling the predictable realities of human vulnerability.

We can turn on curiosity and tune in to possibility, without dropping out of clinical responsibility.

Arthur Lazarus is a former Doximity Fellow, a member of the editorial board of the American Association for Physician Leadership, and an adjunct professor of psychiatry at the Lewis Katz School of Medicine at Temple University in Philadelphia. He is the author of several books on narrative medicine and the fictional series Real Medicine, Unreal Stories. His latest book, a novel, is Against the Tide: A Doctor’s Battle for an Undocumented Patient.